CAP-2003 is comprised of exosomes isolated from the company’s proprietary cardiosphere-derived cells (CDCs). It is being developed as a next-generation therapeutic platform in regenerative medicine and as a vehicle to deliver therapies to cells in the human body.
Exosomes are nano-sized, membrane-enclosed vesicles, or “bubbles,” that are secreted by cells and contain bioactive molecules, including proteins, RNAs and microRNAs. They act as messengers to regulate the functions of neighboring cells. Pre-clinical research has shown that exogenously-administered exosomes can direct or, in some cases, re-direct cellular activity, supporting their therapeutic potential. Their size, ease of crossing cell membranes and ability to communicate in native cellular language make them an exciting class of potential therapeutic agents.
Because of their unique capacities, researchers are increasingly viewing exosomes as vehicles to deliver gene and other therapies to cells in the human body. CAP-2003 offers a unique potential to serve not only as a vehicle for delivering the therapies but also as a therapeutic. Pre-clinical studies have indicated CAP-2003 has potential as a treatment for diseases of inflammation and fibrosis, including Duchenne muscular dystrophy, a fatal genetic disease.
CAP-2003 is immunomodulatory, meaning it can balance the immune system to potentially restore cell damage. The exosomes also have the capacity to reduce inflammation or swelling, which damages cells, and they can reduce cell death and decrease fibrosis or scarring.
Cedars-Sinai Medical Center has granted Capricor worldwide rights to its CDC exosome technology under an exclusive license agreement.
View a list of publications relating to Capricor’s exosome technology.